Showing 661 - 680 results of 100,392 for search '(( 5 nm decrease ) OR ( 5 ((((step decrease) OR (mean decrease))) OR (a decrease)) ))', query time: 1.38s Refine Results
  1. 661
  2. 662

    Decrease in IL-4 measured by standard ELISA. by Albert S. Jun (231619)

    Published 2011
    “…Each ELISA value is an average of two measurements. The decrease in IL-4 in the keratoconus pool (7.6±5 pg/ml), compared to controls (14.2±8.6 pg/ml) was statistically significant (p≤0.05, Mann-Whitney test). …”
  3. 663
  4. 664
  5. 665
  6. 666
  7. 667
  8. 668
  9. 669
  10. 670

    The effect of glibenclamide on channel activity at +20, 0 and -20 mV. by Sajjad Salari (736104)

    Published 2015
    “…The addition of 50 μM glibenclamide resulted in a decreased current jump amplitude and a reduction in P<sub>o</sub>. 100 μM glibenclamide caused a total channel inhibition at +20 and 0 mV (n = 5), but was ineffective at -20 mV. …”
  11. 671
  12. 672

    Nampt inhibition leads to decrease in Rev-erb alpha expression and glucagon secretion in alphaTC1-9 cells and pancreatic alpha cells. by Elaine Vieira (174928)

    Published 2013
    “…<p>(<b>A</b>) <i>Sirt1</i> gene expression in alphaTC1-9 cells treated with 0.5 mM, 11 mM glucose or 500 nM FK 866 for 6 hours (n = 7). …”
  13. 673
  14. 674
  15. 675
  16. 676
  17. 677

    (A) FACS analysis of cell surface markers on untreated or 5 nM Bortezomib treated mature dendritic cells. by Daniela Grabher (383863)

    Published 2013
    “…<p>Maturation marker expression (CD80, CD83 and CD86, MHC class I and MHC class II) on mature dendritic cells and mature dendritic cells treated with 5 nM Bortezomib were measured. Maturation markers show no difference when treated with 5 nM Bortezomib. …”
  18. 678
  19. 679

    LP I<sub>h</sub> metamodulation is rapid and reversible. by Wulf-Dieter C. Krenz (693267)

    Published 2015
    “…<p><b>(A) The time course for metamodulation in 5nM DA</b>. …”
  20. 680

    Discovery of the Triazolo[1,5‑<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance... by Shuai Wang (109515)

    Published 2021
    “…Here, we reported our medicinal chemistry efforts that led to the discovery of the triazolo­[1,5-<i>a</i>]­pyrimidine derivative <b>WS-898</b> as a highly effective ABCB1 inhibitor capable of reversing paclitaxel (PTX) resistance in drug-resistant SW620/Ad300, KB-C2, and HEK293/ABCB1 cells (IC<sub>50</sub> = 5.0, 3.67, and 3.68 nM, respectively), more potent than verapamil and zosuquidar. …”